405 related articles for article (PubMed ID: 32517267)
1. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients.
Ria R; Melaccio A; Racanelli V; Vacca A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517267
[TBL] [Abstract][Full Text] [Related]
2. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
Vincent L; Jin DK; Karajannis MA; Shido K; Hooper AT; Rashbaum WK; Pytowski B; Wu Y; Hicklin DJ; Zhu Z; Bohlen P; Niesvizky R; Rafii S
Cancer Res; 2005 Apr; 65(8):3185-92. PubMed ID: 15833849
[TBL] [Abstract][Full Text] [Related]
3. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow angiogenesis and progression in multiple myeloma.
Ria R; Reale A; De Luisi A; Ferrucci A; Moschetta M; Vacca A
Am J Blood Res; 2011; 1(1):76-89. PubMed ID: 22432068
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
6. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
Song G; Li Y; Jiang G
Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
Dankbar B; Padró T; Leo R; Feldmann B; Kropff M; Mesters RM; Serve H; Berdel WE; Kienast J
Blood; 2000 Apr; 95(8):2630-6. PubMed ID: 10753844
[TBL] [Abstract][Full Text] [Related]
9. Novel biologically based therapies for myeloma.
Anderson KC
Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
[TBL] [Abstract][Full Text] [Related]
10. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
11. Expression of VEGF and its receptors by myeloma cells.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Fonseca R; Greipp PR; Rajkumar SV
Leukemia; 2003 Oct; 17(10):2025-31. PubMed ID: 14513053
[TBL] [Abstract][Full Text] [Related]
12. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
13. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
Bellamy WT
Semin Oncol; 2001 Dec; 28(6):551-9. PubMed ID: 11740808
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
[TBL] [Abstract][Full Text] [Related]
17. [The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma].
Zhang L; Chen SL; Chen WM; Liu JW
Zhonghua Nei Ke Za Zhi; 2005 Feb; 44(2):85-8. PubMed ID: 15840215
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
[TBL] [Abstract][Full Text] [Related]
19. The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy.
Mabeta P; Steenkamp V
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555234
[TBL] [Abstract][Full Text] [Related]
20. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
